Navigation Links
Singapore research team identifies new drug target in deadly form of leukemia
Date:6/3/2013

SINGAPORE A research team led by the Duke-NUS Graduate Medical School (Duke-NUS) in Singapore has identified ways to inhibit the function of a key protein linked to stem cell-like behavior in terminal-stage chronic myeloid leukemia (CML), making it possible to develop drugs that may extend the survival of these patients.

The study, published in the prestigious international journal Proceedings of the National Academy of Sciences, is the result of a long-standing collaboration between Duke-NUS, the Experimental Therapeutics Centre at the Agency for Science, Technology and Research (A*STAR), and the Singapore General Hospital that is focused on developing effective therapies in CML.

CML is a blood cancer that has seen tremendous improvement in treatment outcomes following the introduction of tyrosine kinase inhibitor (TKI) drugs that specifically target the BCR-ABL fusion gene, a genetic abnormality that is characteristic of CML. However, when CML progresses to its terminal stage, known as the blast crisis phase, TKI drugs become ineffective and patients with blast crisis CML rapidly succumb to the disease.

"TKI therapy is highly effective in chronic phase CML, and enables most patients to survive many years. In contrast, patients with blast crisis CML usually succumb to their disease within one year, with most patients dying because they develop drug resistance to TKI therapy," said principal investigator Ong Sin Tiong, associate professor and head of the Laboratory of Hematologic Malignancies in the Cancer and Stem Cell Biology Program at Duke-NUS.

A subset of cells associated with blast crisis CML exhibit characteristics of self-renewing stem cells, suggesting that targeting this particularly malignant and drug-resistant population would be effective in treating blast crisis CML. The team therefore searched for novel targets that will specifically eliminate these cancer stem cells.

Through their efforts, the
'/>"/>

Contact: Juliana Chan
editor@asianscientist.com
65-829-93719
Duke University Medical Center
Source:Eurekalert

Page: 1 2

Related biology news :

1. First in the world - Singapore scientists discover genes responsible for cornea blindness
2. National Heart Centre Singapore develops worlds first human heart cell model
3. Singapore scientists find genes associated with glaucoma, a major cause of eye blindness
4. NUS launches new book on Singapores rainforests and new free digital nature archive
5. Made-in-Singapore H5N1 diagnostic kit -- detects all known strains of H5N1 virus with a single test
6. Researchers develop a faster method to identify Salmonella strains
7. Researchers document acceleration of ocean denitrification during deglaciation
8. Researchers design sensitive new microphone modeled on fly ear
9. Researchers help threatened wheat crops in Asia, Africa
10. Roy J. Carver Charitable Trust funds new research focus at Institute for Genomic Biology
11. U of A medical researchers ID genetic marker for sporadic breast cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... NXT-ID, Inc. (NASDAQ: NXTD and NXTDW) a biometric ... recent success of the Wocket™ smart wallet at CES 2015 in ... named as one of the "11 Hot Products at CES" in a ... CES So Far" by Newseveryday.com and "The top 10 gadgets from CES ...
(Date:1/22/2015)... 21, 2015  Analyst Report Issued by Small Cap IR. In ... that planet-wide, transactions at merchants on the leading payment cards ... of credit, debit, and prepaid cards reached 6.54 billion.  Eight ... fraudulent card usage in 2012, and credit and debit card ...
(Date:1/22/2015)... , Jan. 22, 2015 Research and Markets ... of the "Global Wearable Technologies Market and ... Overview, Trends and Forecast 2014-2020" report to ... are smart devices that can be worn on ...
Breaking Biology News(10 mins):CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 2CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 3$4.80 Near Term Price Target with "Buy" given by CapRock Research for NXT-ID, Inc. (NASDAQ: NXTD) issued by Small Cap IR 2Global Wearable Technologies Market and Applications, Opportunities, Industry Analysis, Segmentation, Size, Growth, Share, Overview, Trends and Forecast 2014-2020 2
... definitely something to be said for first impressions. New ... can take just 20 seconds to detect whether a ... compassionate. The findings reinforce that healthy humans are ... in a tough situation. They also pave the way ...
... 90 percent of cancer deaths are caused by secondary tumors, ... To become mobile and break free from the original ... environment. Many cells have been implicated in this process, including ... collaborator in metastasis is platelets, the blood cells whose normal ...
... rare and neglected diseases that include potential treatments for ... that affects the central nervous system of newborns, a ... a rare lung disease. The six new projects are ... Rare and Neglected Diseases (TRND) program. "These projects ...
Cached Biology News:Is a stranger trustworthy? You'll know in 20 seconds 2MIT: Uncovering a key player in metastasis 2MIT: Uncovering a key player in metastasis 3NIH TRND program announces next round of drug development projects 2NIH TRND program announces next round of drug development projects 3NIH TRND program announces next round of drug development projects 4NIH TRND program announces next round of drug development projects 5
(Date:1/22/2015)... | RBJ today announces the firm brokered a long-term lease ... leading biopharmaceutical company, at Two Ledgemont Center in ... , president, and Brian Cohen , senior vice president, ... at 95 Hayden Ave. Photo - http://photos.prnewswire.com/prnh/20150122/170765 ...
(Date:1/22/2015)... Boulder, CO / Rootstown, OH (PRWEB) January 22, 2015 ... sensitive detection platform, announced today that it has received AOAC-PTM ... O26, O45, O1O3, O111, O121, and O145; collectively referred to ... (E. coli) O157, at 1 colony forming unit (cfu) per ...
(Date:1/22/2015)... January 22, 2015 Controlled Substance Compliance ... which helps companies check the legal requirements around using ... to China. , As their international operations expand ... adopting software solutions built as a result of the ...
(Date:1/22/2015)... , Jan. 22, 2015   Cypher Genomics, Inc., ... Inc. (NASDAQ: SQNM ), the leading ... for next generation noninvasive prenatal tests (NIPT). Through ... technology, called Mantis™, to advance analysis of clinically-relevant ...
Breaking Biology Technology:Transwestern?RBJ Advises Shire in 202,000 SF Lease, Creating Boston's Largest Suburban Biotech Campus 2Crystal Diagnostics Awarded AOAC-PTM Accreditation for the Rapid Detection of “Big 6” E.coli Food Pathogens 2Global Compliance Service for Controlled Substances to Expand to China 2Cypher Genomics and Sequenom Announce Development Agreement 2Cypher Genomics and Sequenom Announce Development Agreement 3Cypher Genomics and Sequenom Announce Development Agreement 4
... Ltd. (Bovespa:,AGEN11), one of the largest provider of integrated ... to its,shareholders and investors that, on April 10, 2008, ... acquisition of 264,000 m3 of,biodiesel, for delivery between July ... was to ensure supply of the necessary volumes for ...
... Inc.,(Amex: SGN ) has confirmed that it has ... Executive Officer, Dr. Lowell T. Harmison, has,scheduled a webcast ... Dr. Harmison stated: "Now that Signalife has closed filing ... shipping,product, I am pleased to provide direction on new ...
... SIAL ), will hold its quarterly conference ... 23, 2008, at 11:00 a.m. Eastern Time,(10 a.m. ... by Thomson/CCBN and can be accessed at,Sigma- Aldrich,s ... webcast is also being distributed through the Thomson ...
Cached Biology Technology:Signalife Announces Webcast 2Signalife Announces Webcast 3Sigma-Aldrich Corporation 1st Quarter 2008 Earnings Conference Call 2
Human RXR beta/NR2B2 MAb (Clone H7341) Keywords: RXRbeta, RXRbeta, Retinoid X Receptor beta...
Human SOST Affinity Purified Polyclonal Ab...
BOND ELUT MATRIX-C18, 25 mg ...
Prepared from plasminogen by activation with immobilized human uPA...
Biology Products: